Drug Trial Radar · NCT06159673
ACP-204 in Adults With Alzheimer's Disease Psychosis
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,074
Planned (sponsor's estimate)
Start
Nov 14, 2023
Primary completion
Jan 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- ACADIA Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 95 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP * Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first. * Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B will be performed independently of each other and will commence after enrollment of Part 1. All 3 substudies will be analyzed independently of each other. Each substudy individually will consist of a screening period (up to 49 days); a double-blind treatment period (6 weeks); a safety follow-up period (30 days) for patients not rolling over into an open-label extension study; and vital status follow-up (for patients who terminated their substudy early).
Conditions
- Alzheimer's Disease Psychosis
Interventions
ACP-204Drug
ACP-204 is a potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor subtype 2A.
PlaceboDrug
ACP-204 matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D) total score change from baseline (Substudies 1, 2A, 2B)Time frame: From baseline to Week 6
Locations
155 sites in 12 countries. Site status is shown where the registry gives one.
Chandler Clinical Trials
Chandler, Arizona · Withdrawn
Clinical Endpoint LLC
Scottsdale, Arizona · Recruiting
Advanced Research Center, Inc.
Anaheim, California · Withdrawn
ATP Clinical Research
Costa Mesa, California · Recruiting
Neuro-Pain Medical Center
Fresno, California · Recruiting
National Institute of Clinical Research
Garden Grove, California · Terminated
Havana Research Institute LLC
Pasadena, California · Recruiting
Quantum Clinical Research, Inc.
Pasadena, California · Recruiting
Humanity Clinical Research Corp
Aventura, Florida · Recruiting
Arrow Clinical Trials
Daytona Beach, Florida · Recruiting
First Excellent Research Group
Doral, Florida · Recruiting
New Life Medical Research Center Inc.
Hialeah, Florida · Recruiting
Reliable Clinical Research LLC.
Hialeah, Florida · Recruiting
Homestead Associates in Research Inc.
Miami, Florida · Recruiting
Premier Clinical Research Institute, Inc.
Miami, Florida · Recruiting
Central Miami Medical Institute
Miami, Florida · Withdrawn
Advanced Clinical Research Network, Corp
Miami, Florida · Recruiting
Verus Clinical Research
Miami, Florida · Recruiting
Future Care Solution, LLC
Miami, Florida · Recruiting
MediClear Medical & Research Center, Inc.
Miami, Florida · Recruiting
ABBA Medical Group LLC
Miami, Florida · Recruiting
Visionary Investigators Network
Miami, Florida · Withdrawn
Quantum Clinical Trials
Miami Beach, Florida · Recruiting
New Med Research
Miami Gardens, Florida · Recruiting
Floridian Neuroscience Institutue
Miami Lakes, Florida · Recruiting
Combined Research Orlando Phase I IV
Orlando, Florida · Recruiting
Psych Me Medical Research Inc
Tampa, Florida · Withdrawn
Neuroscience Research Institute
West Palm Beach, Florida · Recruiting
Agile Clinical Research Trials LLC
Atlanta, Georgia · Recruiting
Revive Research Institute, Inc.
Elgin, Illinois · Withdrawn
Grace Research, LLC
Shreveport, Louisiana · Recruiting
CBH Health LLC, dba CenExcel Gaithersburg
Gaithersburg, Maryland · Recruiting
Khan Revive Research Institute
Rochester Hills, Michigan · Withdrawn
Tekton Research, LLC
St Louis, Missouri · Recruiting
Alivation Research, LLC
Lincoln, Nebraska · Withdrawn
Advanced Memory Research Institute of New Jersey
Marlton, New Jersey · Recruiting
Dent Neurologic Institute
Amherst, New York · Withdrawn
Finger Lakes Clinical Research
Rochester, New York · Withdrawn
SUNY Upstate Medical University
Syracuse, New York · Recruiting
Regional Neurological Associates
The Bronx, New York · Withdrawn
Showing 40 of 155 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.